Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAEL D KOHEN

Allopathic & Osteopathic Physicians Allergy & Immunology

NPI
1013909951
CMS profile
1145
Location
DAYTONA BEACH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$4,369.74

189 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $4,130.22 188
Grant $239.52 1

By paying entity

PY2022 · entire year · sorted by reported total

Page 4 of 4; records 151–189 of 189 matching records. This page contains 39 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAEL D KOHEN

NPI 1013909951 · CMS profile ID 1145

Allopathic & Osteopathic Physicians / Allergy & Immunology

DAYTONA BEACH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–189 of 189 matching records. This page contains 39 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1013909951?year=2022&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAEL D KOHEN, NPI 1013909951, CMS profile ID 1145. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–189 of 189 matching records. This page contains 39 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1013909951?year=2022&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). MICHAEL D KOHEN, NPI 1013909951, CMS profile ID 1145. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–189 of 189 matching records. This page contains 39 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1013909951?year=2022&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
MICHAEL D KOHEN, NPI 1013909951, CMS profile ID 1145, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–189 of 189 matching records. This page contains 39 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1013909951?year=2022&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

189 matching records · $4,369.74 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 189 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–189 of 189.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $18.9703/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939214955 CMS
Janssen Biotech, Inc. $17.6603/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885656047 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.3103/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887454669 CMS
AstraZeneca Pharmaceuticals LP $13.3103/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914708389 CMS
Amgen Inc. $16.5002/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939214947 CMS
Novartis Pharmaceuticals Corporation $23.4102/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893848707 CMS
PFIZER INC. $19.4002/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949069261 CMS
ABBVIE INC. $16.0602/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893090047 CMS
Amgen Inc. $21.9102/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939214945 CMS
Amgen Inc. $12.9402/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939214919 CMS
ABBVIE INC. $2.1802/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893090045 CMS
AstraZeneca Pharmaceuticals LP $23.9202/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915642677 CMS
Aurinia Pharma U.S., Inc. $21.9702/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954087033 CMS
AstraZeneca Pharmaceuticals LP $16.9502/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915781409 CMS
Janssen Biotech, Inc. $13.7302/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885656077 CMS
ABBVIE INC. $17.9302/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893090043 CMS
UCB, Inc. $17.6202/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 907974539 CMS
Mallinckrodt Hospital Products Inc. $18.1202/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937506963 CMS
PFIZER INC. $13.7502/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949064167 CMS
GlaxoSmithKline, LLC. $26.0802/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944316667 CMS
PFIZER INC. $2.4902/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949136355 CMS
AstraZeneca Pharmaceuticals LP $14.6802/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915584153 CMS
ABBVIE INC. $24.2902/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893090041 CMS
Amgen Inc. $21.3902/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939214933 CMS
Novartis Pharmaceuticals Corporation $18.2901/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893848703 CMS
Actelion Pharmaceuticals US, Inc. $22.8401/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885378819 CMS
Lilly USA, LLC $20.7101/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918196361 CMS
ABBVIE INC. $15.9201/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893090039 CMS
Amgen Inc. $12.7201/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939214931 CMS
UCB, Inc. $23.8001/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 907974543 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $19.9201/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887454671 CMS
PFIZER INC. $21.2601/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949058785 CMS
Aurinia Pharma U.S., Inc. $20.9201/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954087029 CMS
ABBVIE INC. $25.8701/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893090037 CMS
AstraZeneca Pharmaceuticals LP $24.7501/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915683179 CMS
Horizon Therapeutics plc $17.0701/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937645729 CMS
Amgen Inc. $19.4501/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939214917 CMS
ABBVIE INC. $25.0001/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893090035 CMS
UCB, Inc. $24.9301/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 907974545 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,629.98 190
PY2020 $3,283.87 168
PY2021 $3,730.72 193
PY2022 $4,369.74 189
PY2023 $4,213.26 179
PY2024 $3,413.76 151
PY2025 $3,588.32 140

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $507,330.80 50
PY2024 Principal investigator $415,151.82 175
PY2023 Principal investigator $353,807.34 171
PY2022 Principal investigator $421,399.90 123
PY2021 Principal investigator $447,225.41 113
PY2020 Recipient $2,282.40 2
PY2020 Principal investigator $565,172.85 78
PY2019 Principal investigator $830,213.62 77

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

50 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $134.66 12/31/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH
A Phase 3b/4 Randomized, Double-Blind, Double Dummy, Active Comparator-Controlled Study, Comparing the Efficacy and Safety of Upadacitinib Versus Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis on a Stable Background of MTX and who had an Inadequate Response or Intolerance to a Single TNF Inhibitor (SELECT- SWITCH) No dispute reported 06/30/2026 1202532544
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,858.70 12/17/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223289908
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,820.48 12/17/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223289910
Principal investigator 1 ABBVIE INC. $3,738.15 12/04/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202526762
Principal investigator 1 ABBVIE INC. $17,606.20 12/04/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202526764
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,909.25 12/03/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223289190
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $6,790.10 11/14/2025 Non-covered Recipient Entity
Millennium Research
Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus No dispute reported 06/30/2026 1235995687
Principal investigator 1 ABBVIE INC. $11,092.65 11/04/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202520255
Principal investigator 1 ABBVIE INC. $2,504.40 11/04/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202520257
Principal investigator 1 Janssen Research & Development, LLC $6,550.00 10/20/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH LLC
A Multi Center Randomized Double blind Placebo controlled Parallel group Study of Nipocalimab in Adult Participants with Active Systemic Lupus Erythematosus No dispute reported 06/30/2026 1175345803
Principal investigator 1 ABBVIE INC. $5,320.50 10/09/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202513891
Principal investigator 1 ABBVIE INC. $4,230.10 10/09/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202513893
Principal investigator 1 ABBVIE INC. $61,056.45 10/08/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202513505
Principal investigator 1 ABBVIE INC. $3,100.00 09/11/2025 Non-covered Recipient Entity
ACHIEVE CLINICAL RESEARCH LLC
Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine (CORNERSTONE) No dispute reported 06/30/2026 1202510778
Principal investigator 1 ABBVIE INC. $6,986.70 09/03/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202507155
Principal investigator 1 ABBVIE INC. $6,424.80 09/03/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202507157
Principal investigator 1 ABBVIE INC. $2,215.88 09/03/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH LLC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202507159
Principal investigator 1 Amgen Inc. $1,234.08 08/19/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH, LLC
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjgren's Syndrome No dispute reported 06/30/2026 1246644734
Principal investigator 1 ABBVIE INC. $2,527.00 08/06/2025 Non-covered Recipient Entity
ACHIEVE CLINICAL RESEARCH LLC
Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine (CORNERSTONE) No dispute reported 06/30/2026 1202503525
Principal investigator 1 ABBVIE INC. $6,257.40 08/05/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202502162
Principal investigator 1 ABBVIE INC. $80,907.45 08/05/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202502164
Principal investigator 1 ABBVIE INC. $5,285.00 07/08/2025 Non-covered Recipient Entity
ACHIEVE CLINICAL RESEARCH LLC
Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine (CORNERSTONE) No dispute reported 06/30/2026 1202497126
Principal investigator 1 ABBVIE INC. $18,785.55 07/02/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202494567
Principal investigator 1 ABBVIE INC. $13,419.60 07/02/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202494569
Principal investigator 1 Amgen Inc. $14,120.00 06/04/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246644730
Principal investigator 1 ABBVIE INC. $5,179.05 06/03/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202488277
Principal investigator 1 ABBVIE INC. $2,479.13 06/03/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH LLC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202488279
Principal investigator 1 Amgen Inc. $1,698.42 06/02/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH, LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246644739
Principal investigator 1 Janssen Research & Development, LLC $12,193.20 05/22/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH LLC
A Multi Center Randomized Double blind Placebo controlled Parallel group Study of Nipocalimab in Adult Participants with Active Systemic Lupus Erythematosus No dispute reported 06/30/2026 1175345795
Principal investigator 1 ABBVIE INC. $10,278.75 05/06/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202481447
Principal investigator 1 ABBVIE INC. $9,189.50 05/06/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202481449
Principal investigator 1 UCB SA $593.34 04/07/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. No dispute reported 06/30/2026 1246659442
Principal investigator 1 ABBVIE INC. $8,610.00 04/03/2025 Non-covered Recipient Entity
ACHIEVE CLINICAL RESEARCH LLC
Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine (CORNERSTONE) No dispute reported 06/30/2026 1202471280
Principal investigator 1 ABBVIE INC. $5,781.90 04/03/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202471289
Principal investigator 1 ABBVIE INC. $9,319.50 04/03/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202471291
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,000.00 04/02/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223277512
Principal investigator 1 UCB SA $52,140.00 03/26/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. No dispute reported 06/30/2026 1246658390
Principal investigator 1 ABBVIE INC. $1,925.00 03/07/2025 Non-covered Recipient Entity
ACHIEVE CLINICAL RESEARCH LLC
P24-880 - Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine (CORNERSTONE) No dispute reported 06/30/2026 1202459377
Principal investigator 1 ABBVIE INC. $13,452.10 03/07/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH LLC
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202461392
Principal investigator 1 ABBVIE INC. $2,259.08 03/06/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH LLC
M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202457883
Principal investigator 1 ABBVIE INC. $6,347.85 03/06/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH LLC
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202458237
Principal investigator 1 ABBVIE INC. $16,574.70 02/06/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH LLC
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202447442
Principal investigator 1 ABBVIE INC. $9,021.60 02/05/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH LLC
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202443969
Principal investigator 1 ABBVIE INC. $488.63 02/05/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH LLC
M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202444354
Principal investigator 1 SANOFI US SERVICES INC. $1,550.00 02/05/2025 Non-covered Recipient Entity
Millennium Research LLC
Phase 2a, Randomized, Double-blind, Placebo-controlled Trial of PRV-3279 EVAluation In Lupus (PREVAIL-2) No dispute reported 06/30/2026 1226138847
Principal investigator 1 SANOFI US SERVICES INC. $600.00 02/05/2025 Non-covered Recipient Entity
Millennium Research LLC
Phase 2a, Randomized, Double-blind, Placebo-controlled Trial of PRV-3279 EVAluation In Lupus (PREVAIL-2) No dispute reported 06/30/2026 1226138851
Principal investigator 1 ABBVIE INC. $10,000.00 01/28/2025 Non-covered Recipient Entity
ACHIEVE CLINICAL RESEARCH LLC
P24-880 - Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine (CORNERSTONE) No dispute reported 06/30/2026 1202441603
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $25,361.00 01/06/2025 Non-covered Recipient Entity
Millennium Research
A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) No dispute reported 06/30/2026 1235995685
Principal investigator 1 ABBVIE INC. $788.80 01/02/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH LLC
M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202433469
Principal investigator 1 ABBVIE INC. $3,624.15 01/02/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH LLC
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202433474